

Challenges in the conduct of large simple trials of important interventions in resource-poor settings: The CREATE and ECLA trial programs

American Heart Journal

148, 1068-1078

DOI: [10.1016/j.ahj.2004.08.033](https://doi.org/10.1016/j.ahj.2004.08.033)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation. JAMA - Journal of the American Medical Association, 2005, 293, 427.	3.8	137
2	Simple Principles of Clinical Trials Remain Powerful. JAMA - Journal of the American Medical Association, 2005, 293, 489.	3.8	28
3	Reviparin in Acute Myocardial Infarction—Reply. JAMA - Journal of the American Medical Association, 2005, 293, 2595.	3.8	16
4	Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 437.	3.8	581
5	Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ELCA Randomized Controlled Trial. Yearbook of Cardiology, 2006, 2006, 226-228.	0.0	0
6	Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2007, 298, 2399.	3.8	149
7	Targeting Glucose in Acute Myocardial Infarction. Diabetes Care, 2007, 30, 3026-3028.	4.3	12
8	Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems. Journal of Clinical Pharmacology, 2007, 47, 1074-1086.	1.0	58
10	Glucose control peri-myocardial infarction. Internal Medicine Journal, 2008, 38, 341-344.	0.5	2
11	Randomized Trials in Vulnerable Populations. Clinical Trials, 2008, 5, 61-69.	0.7	20
12	Anticoagulant Agents. Fundamental and Clinical Cardiology, 2008, , 195-232.	0.0	0
13	The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovascular Research, 2008, 79, 259-268.	1.8	79
14	Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. Diabetes and Vascular Disease Research, 2008, 5, 276-284.	0.9	8
15	Acute ST-Segment Elevation Myocardial Infarction. Chest, 2008, 133, 708S-775S.	0.4	110
16	Insulin Treatment in Intensive Care Patients. Hormone Research in Paediatrics, 2009, 71, 2-11.	0.8	11
17	Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion. Basic Research in Cardiology, 2009, 104, 203-210.	2.5	57
18	The Gap Between Clinical Trials and Clinical Practice: The Use of Pragmatic Clinical Trials to Inform Regulatory Decision Making. Clinical Pharmacology and Therapeutics, 2010, 87, 351-355.	2.3	46
19	Complications and Management of Chronic Kidney Disease. , 2010, , 145-163.		1

#	ARTICLE	IF	CITATIONS
20	Is the Large Simple Trial Design Used for Comparative, Post-Approval Safety Research?. Drug Safety, 2011, 34, 799-820.	1.4	15
21	The role of insulin therapy and glucose normalisation in patients with acute coronary syndrome. Netherlands Heart Journal, 2011, 19, 79-84.	0.3	8
22	A New Look at an Old Therapy. JAMA - Journal of the American Medical Association, 2012, 307, 1972.	3.8	9
23	Management of Hyperglycemia in a Hospitalized Patient with Diabetes Mellitus and Cardiovascular Disease. American Journal of Cardiology, 2012, 110, 24B-31B.	0.7	13
24	Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia. Contemporary Clinical Trials, 2013, 34, 239-247.	0.8	7
26	The Patient-Centered Outcomes Research Network. North Carolina Medical Journal, 2014, 75, 204-210.	0.1	35
27	Prise en charge du diab�tologique apr�s infarctus du myocarde. , 2014, , 353-358.		0
28	Nonantithrombotic Medical Options in Acute Coronary Syndromes. Circulation Research, 2014, 114, 1944-1958.	2.0	15
29	Glucose-Insulin-Potassium Solution Protects Ventricular Myocytes of Neonatal Rat in an <i>In Vitro</i> Coverslip Ischemia/Reperfusion Model. Korean Circulation Journal, 2015, 45, 234.	0.7	15
30	Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction. Cardiovascular Medicine, 2015, , 461-504.	0.0	1
31	Quality of inpatient care in public and private hospitals in Sri Lanka. Health Policy and Planning, 2015, 30, i46-i58.	1.0	18
32	A predictive model to identify patients with suspected acute coronary syndromes at high risk of cardiac arrest or in-hospital mortality: An IMMEDIATE Trial sub-study. IJC Heart and Vasculature, 2015, 9, 37-42.	0.6	0
33	Reperfusion Therapy for Acute Myocardial Infarction. , 0, , .		0
34	Medical Treatment of Unstable Angina, Acute Non-ST-Elevation Myocardial Infarction, and Coronary Artery Spasm. , 2007, , 937-961.		0
35	Myocyte Protection by Pharmacological Therapy. Fundamental and Clinical Cardiology, 2008, , 233-247.	0.0	0
36	Prise en charge du diab�tologique apr�s infarctus du myocarde. , 2010, , 346-351.		0
39	Prise en charge du diab�tologique apr�s infarctus du myocarde. , 2019, , 469-474.		0
40	Cardiological Society of India. AsiaIntervention, 2021, 7, 76-78.	0.1	2

#	ARTICLE	IF	CITATIONS
42	Reviparin in Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 2595.	3.8	0